Bergen, Norway – April 7, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel selective AXL inhibitors for serious unmet medical needs, announces that the Board of Directors today approved the 2021 annual financial statements prepared in accordance with International Financial Reporting Standards (IFRS).
The 2021 annual report and the ESEF file are attached to this press release and are also available on BerGenBio ASAthe website of https://www.bergenbio.com/investors/reports/
For BerGenBio: Martin Olin CEO, BerGenBio ASA
Skei RuneCFO, BerGenBio ASA
International media relations
Marie-Jane Elliott, Chris Welsh, Lucy Plume
Consilium Strategic Communications
+44 20 3709 5700
On BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on the development of transformative drugs targeting AXL as a potential cornerstone for the treatment of aggressive diseases, including immune-evasive and treatment-resistant cancers. The Company’s proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in an extensive Phase II clinical development program focused on combination and single-agent therapy in cancer and COVID-19. A first-in-class blocking anti-AXL antibody, tilvestamab, is in phase I clinical trials. In parallel, BerGenBio is developing companion diagnostic tests to potentially identify patient populations most likely to benefit from AXL inhibition: this should facilitate more efficient registrational trials supporting a precision medicine-based commercialization strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, United Kingdom. The company is listed on Oslo Stock Exchange (symbol: BGBIO). For more information visit www.bergenbio.com
This announcement may contain forward-looking statements, which as such are not historical facts, but are based on various assumptions, many of which are based, in turn, on other assumptions. These assumptions are inherently subject to important known and unknown risks, uncertainties and other important factors. These risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements in accordance with Section 5-12 of the Norwegian Securities Act.
(c) Decision 2022. All rights reserved., sources Press Releases – English